

DIAGNOS

Interim Condensed Consolidated Financial Statements - Unaudited

Three-month and Nine-month Periods ended December 31, 2018

DIAGNOS Inc.

Note to reader: These Unaudited Interim Condensed Consolidated Financial Statements have not been reviewed by our auditor.

DIAGNOS Inc.

Interim Condensed Consolidated Statements of Financial Position (unaudited)
(amounts in Canadian dollars)

	Note	As at	
		December 31, 2018	March 31, 2018
		\$	
ASSETS			
Current			
Cash		417,982	150,291
Short-term investments	5	800,622	85,984
Accounts receivable	6	438,465	531,132
Prepaid expenses		45,523	22,544
		<u>1,702,592</u>	<u>789,951</u>
Non-current			
Investments	7	6,000	476,803
Capital assets		145,784	256,734
Intangible assets		-	759
		<u>151,784</u>	<u>734,296</u>
Total assets		<u>1,854,376</u>	<u>1,524,247</u>
LIABILITIES			
Current			
Accounts payable and accrued liabilities	8	650,789	614,972
Deferred revenue	18	66,617	31,893
Convertible debentures	10	1,636,258	-
Leases	11	38,918	16,238
		<u>2,392,582</u>	<u>663,103</u>
Non-current			
Convertible notes	9	865,891	829,910
Convertible debentures	10	2,902,951	3,635,330
Leases	11	40,670	32,589
		<u>3,809,512</u>	<u>4,497,829</u>
Total liabilities		<u>6,202,094</u>	<u>5,160,932</u>
Commitments	14		
SHAREHOLDERS' DEFICIENCY			
Share capital	12	23,284,003	21,881,166
Reserve	13	8,547,289	7,532,632
Deficit		(36,202,615)	(33,111,012)
Investments revaluation reserve		(33,500)	(24,573)
Foreign exchange differences		57,105	85,102
		<u>(4,347,718)</u>	<u>(3,636,685)</u>
Total liabilities and shareholders' deficiency		<u>1,854,376</u>	<u>1,524,247</u>

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

DIAGNOS Inc.

Interim Condensed Consolidated Statements of Earnings and Comprehensive Loss (unaudited)

(amounts in Canadian dollars)

	Note	Three-month period ended December 31,			Nine-month period ended December 31,				
		2018	2017		2018	2017			
		Total	Continued operations	Discontinued operations (note 20)	Total	Total	Continued operations	Discontinued operations (note 20)	Total
		\$			\$				
Revenue	18	94,511	937,426	-	937,426	235,322	1,226,228	320,000	1,546,228
Expenses									
Costs of services and research and development		276,944	429,172	-	429,172	877,063	974,135	24,207	998,342
Selling and administrative		573,485	864,061	-	864,061	1,703,584	2,307,420	47,964	2,355,384
	16	850,429	1,293,233	-	1,293,233	2,580,647	3,281,555	72,171	3,353,726
Income (loss) before other items		(755,918)	(355,807)	-	(355,807)	(2,345,325)	(2,055,327)	247,829	(1,807,498)
Other income	21	-	-	-	-	15,857	-	-	-
Interest expense	16	(280,640)	(188,553)	-	(188,553)	(761,521)	(671,793)	-	(671,793)
Gain (loss) on disposal of capital assets		2,892	-	-	-	(614)	-	-	-
Gain on disposal of mining division		-	-	-	-	-	-	623,919	623,919
Net income (loss)		(1,033,666)	(544,360)	-	(544,360)	(3,091,603)	(2,727,120)	871,748	(1,855,372)
Other comprehensive income items									
Net change in fair value of available-for-sale financial assets		(15,507)	105,000	-	105,000	(34,434)	(117,382)	-	(117,382)
Net change in foreign exchange translation		1,739	10,877	-	10,877	(27,997)	39,936	-	39,936
Realized loss on disposal of available-for-sale financial assets		25,507	142,564	-	142,564	25,507	142,564	-	142,564
		11,739	258,441	-	258,441	(36,924)	65,118	-	65,118
Comprehensive (loss) income		(1,021,927)	(285,919)	-	(285,919)	(3,128,527)	(2,662,002)	871,748	(1,790,254)
Basic and diluted comprehensive (loss) income per share		(0.01)	(0.00)	-	(0.00)	(0.02)	(0.02)	0.01	(0.01)
Weighted-average number of common shares outstanding		194,880,722		172,421,265		180,352,792		168,166,111	

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

DIAGNOS Inc.

Interim Condensed Consolidated Statements of Changes in Equity (unaudited)

(amounts in Canadian dollars)

Nine-month period ended December 31, 2018

	Note	Share capital	Reserve	Deficit	Foreign exchange differences	Investments revaluation reserve	Total shareholders' deficiency
\$							
Balance, beginning of period		21,881,166	7,532,632	(33,111,012)	85,102	(24,573)	(3,636,685)
Net loss		-	-	(3,091,603)	-	-	(3,091,603)
Other comprehensive loss items		-	-	-	(27,997)	(8,927)	(36,924)
Issuance of common shares	12	1,419,365	-	-	-	-	1,419,365
Issuance of conversion options	10,13	-	134,013	-	-	-	134,013
Issuance of warrants	10,13	-	692,317	-	-	-	692,317
Issue expenses	12,13	(16,528)	(12,519)	-	-	-	(29,047)
Stock-based compensation expense	12,13	-	200,846	-	-	-	200,846
Balance, end of period		23,284,003	8,547,289	(36,202,615)	57,105	(33,500)	(4,347,718)

Nine-month period ended December 31, 2017

	Note	Share capital	Reserve	Deficit	Foreign exchange differences	Investments revaluation reserve	Total shareholders' deficiency
\$							
Balance, beginning of period		20,368,019	6,865,731	(30,213,847)	71,825	(6,000)	(2,914,272)
Net loss		-	-	(1,855,372)	-	-	(1,855,372)
Other comprehensive loss		-	-	-	39,936	25,182	65,118
Issuance of common shares	12	1,513,147	-	-	-	-	1,513,147
Issuance of conversion options	10,13	-	637,228	-	-	-	637,228
Issuance of warrants	10,13	-	88,022	-	-	-	88,022
Issuance expenses	13	-	(37,841)	-	-	-	(37,841)
Stock-based compensation expense	12,13	-	124,917	-	-	-	124,917
Balance, end of period		21,881,166	7,678,057	(32,069,219)	111,761	19,182	(2,379,053)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

DIAGNOS Inc.

Interim Condensed Consolidated Statements of Cash Flows (unaudited)

(amounts in Canadian dollars)

	Note	Nine-month period ended December 31,	
		2018	2017
		\$	
Cash flows from operating activities			
Net loss		(3,091,603)	(1,855,372)
Items not affecting cash			
Depreciation of capital assets		157,519	161,546
Amortization of intangible assets		759	7,560
Accretion on leases	11	3,561	3,235
Accretion on convertible notes	9	35,981	-
Accretion on convertible debentures	10	282,009	293,410
Loss on disposal of capital assets		614	-
Gain on disposal of mining division		-	(623,919)
Compounded interest		13,356	(4,950)
Stock-based compensation expense	12,13	200,846	124,917
Share of loss from equity accounted investment		-	142,564
Gain on disposal of investments	7	25,507	-
		(2,371,451)	(1,751,009)
Payment of interest		257,000	583,729
Net change in operating working capital items		140,229	29,629
		(1,974,223)	(1,137,651)
Cash flows from investing activities			
Additions to short-term investments		(640)	(565)
Proceeds from disposal of short-term investments	5	36,002	-
Acquisition of short term investments	5	(750,000)	-
Proceeds from disposal of investments	7	436,369	-
Additions to capital assets		(50,804)	(273,979)
Proceeds from sale of capital assets		3,621	-
Other		(27,997)	39,936
		(353,449)	(234,608)
Cash flows from financing activities			
Issuance of common shares, net of issue expenses	12	2,063,662	373,147
Repayment of short term loan		-	(533,000)
Leases	11	47,063	22,247
Lease payments	11	(19,863)	(13,271)
Issuance of convertible notes, net of issue expenses	9	-	794,905
Issuance of convertible debentures, net of issue expenses	10	761,500	1,789,330
Issuance of conversion options, net of issue expenses	13	-	604,544
Issuance of warrants, net of issue expenses	13	-	82,865
Payment of interest		(257,000)	(583,729)
		2,595,362	2,537,038
Net change in cash		267,691	1,164,779
Cash, beginning of period		150,291	189,861
Cash, end of period		417,982	1,354,640
Non-cash transactions			
Payment of interest in shares	9	45,000	-
Value of payment in shares of customer receivables		-	274,292
Payments in shares of mining division	20	-	640,000
Issuance of convertible debentures	10	-	150,000
Conversion of debentures into common shares	10	-	1,140,000

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

DIAGNOS Inc.

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

December 31, 2018, March 31, 2018 and December 31, 2017

(amounts in Canadian dollars)

1. Going concern assumption

These interim condensed consolidated financial statements have been prepared on a going concern basis, which assumes that the Corporation will continue to operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

In order to address these uncertainties, the Corporation is evaluating the implementation of some or all of the following measures:

- Continue the process of renewing contracts
- Reduce operating costs with temporary staff lay-offs, curtail certain consulting and travel costs
- Continue to seek debt financing
- Continue to seek equity financing consisting of common shares and stock purchase warrants
- Continue to evaluate possible M&A opportunities

The Corporation believes that if it were to be successful in implementing some or all of the above risk mitigating measures, it will be able to continue as a going concern. There remains however, significant risk and uncertainty associated with implementing any of these measures which are dependent on a number of factors outside of the Corporation's control. The material uncertainty cast significant doubt regarding the ability to continue as a going concern.

These interim condensed consolidated financial statements do not reflect any adjustments that would be necessary if the going concern basis was not appropriate. Such adjustments, if required, may be material.

2. Statutes of incorporation and nature of activities

DIAGNOS Inc. ("the Corporation") is incorporated under the Canada Business Corporations Act and the subsidiaries under the applicable regulations in their respective countries. The main office is located at 7005 Taschereau Blvd., Suite 340, Brossard, Quebec, Canada. The shares of the Corporation are listed on the TSX Venture Exchange.

The Corporation provides software-based interpretation services to assist health specialists in the detection of diabetic retinopathy.

These interim condensed consolidated financial statements have been approved and authorized for issue by the Board of Directors of the Corporation on February 27, 2019.

3. Basis of presentation and changes in significant accounting policies

Basis of consolidation

These interim condensed consolidated financial statements include the accounts of the Corporation and those of its subsidiaries. Subsidiaries consist of entities over which the Corporation has right, or is exposed, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Subsidiaries' financial statements are included in the consolidated financial statements from the date that control commences until the date that control ceases. Subsidiaries' year end and accounting policies are aligned with those adopted by the Corporation.

Percentage of interest in the Corporation's subsidiaries and associates, as at December 31, 2018, are as follows:

Name of entity	Location	Type of entity	Percentage of ownership
DMS & Technologies Inc.	Canada	Subsidiary	100%
8913404 Canada Inc.	Canada	Subsidiary	100%
Diagnos (USA) Inc.	United States of America	Subsidiary	100%
Diagnos Poland sp. Z o.o.	Poland	Subsidiary	100%
Diagnos Internacional SA de CV	Mexico	Subsidiary	99.8%
Diagnos Healthcare (India) Private Limited	India	Subsidiary	99.74%
SARL Diagnos Medical	Algeria	Associate	48%

DIAGNOS Inc.

Inter-company transactions and balances and any unrealized revenue and expense are eliminated in preparing the consolidated financial statements.

Investment in associate is accounted for using the equity method. The carrying amount of the investment in associate is increased or decreased to recognize the Corporation's share of the profit or loss and other comprehensive income of the associate, adjusted where necessary to ensure consistency with the accounting policies of the Corporation. Unrealized gains and losses on transactions between the Corporation and its associate are eliminated to the extent of the Corporation's interest in the entity. Where unrealized losses are eliminated, the underlying asset is also tested for impairment.

Changes in significant accounting policies

These interim condensed consolidated financial statements were prepared in accordance with standard IAS 34 – Interim Financial Reporting and do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"). They, however, include specific complimentary notes in order to provide information necessary to assess the financial situation of the Corporation at period end since its last annual consolidated financial statements dated March 31, 2018.

Except for the changes below, the accounting policies used to prepare these interim unaudited condensed consolidated financial statements are those described in the last annual consolidated financial statements of the Corporation and have been applied throughout the period unless otherwise stated. This is the third set of the Corporation's financial statements where IFRS 15 and IFRS 9 have been applied. Changes to significant accounting policies are described hereinafter.

a) Revenue

On April 1, 2018, the Corporation adopted IFRS 15 – Revenue from contracts with customers. The adoption of IFRS 15 did not have an impact to the comparative figures presented in these interim condensed consolidated financial statements.

The Corporation operates in one reportable segment, healthcare services. Revenue from healthcare services typically arises from access to CARA, a web-based software tool used by healthcare professionals principally for the detection of diabetic retinopathy. Access to CARA usually includes sales support for the duration of the contract. In some cases, revenue may also arise from added services such as providing workforce to a client for the customization and the deployment of CARA. The Corporation accounts for the different services separately if they are distinct and the selling prices can be reasonably estimated.

The Corporation also renders consulting services to companies active in the healthcare sector and the mining sector. As this line of business is not strategic to the development of the Corporation, revenue amounts derived from consulting services are not presented separately.

Revenue is recognized when there is a transfer of control over a product or service to a customer, usually over the period in which the services are rendered. Revenue is measured based on the consideration specified in a contract with a customer and excludes sales tax amounts and other amounts collected on behalf of third parties. Billing of services is usually done on a monthly basis. Contract assets representing unbilled services rendered are presented under "Accounts receivable" in the consolidated statements of financial position. Contract liabilities representing amounts invoiced before the recognition of services or goods are presented under "Deferred revenue" in the consolidated statements of financial position.

Government grants

A government grant is recognized when there is reasonable assurance that the Corporation has (i) complied with all applicable conditions and (ii) the money will be received.

A grant related to assets is presented in the consolidated statement of financial position by deducting the grant in arriving at the carrying amount of the asset. A grant related to income is presented as other income in the consolidated statement of earnings and comprehensive loss.

b) Financial instruments

On April 1, 2018, the Corporation adopted IFRS 9 – Financial instruments. The adoption of IFRS 9 did not have an impact to the comparative figures presented in these interim condensed consolidated financial statements.

The following table below presents the new measurement categories under IFRS 9 compared to the original measurement categories as at March 31, 2018 for each class of the Corporation’s financial assets and financial liabilities.

Description	New classification as of April 1, 2018	Original classification as of March 31, 2018
Cash	Financial assets at amortized cost	Loans and receivables
Short-term investments	Financial assets at Fair Value Through Profit or Loss (“FVTPL”)	Fair Value Through Profit or Loss (“FVTPL”)
Accounts receivable, except tax credits and sales taxes	Financial assets at amortized cost	Loans and receivables
Investments in entities other than subsidiaries and associates	Financial assets at Fair Value through Other Comprehensive Income (“FVOCI”) ¹	Available for sale
Accounts payable and accrued liabilities (except salaries and benefits and sales taxes), convertible notes and convertible debentures	Financial liabilities at amortized cost	Amortized cost

The Corporation aggregates its financial instruments into classes based on their nature and characteristics. Management determines the classification when the instruments are initially recognized, which is normally on the date of the transaction. Transaction costs related to financial instruments are measured initially at fair value, except for transaction costs related to FVTPL financial assets which are expensed as incurred and added to the carrying value of the asset or netted against the carrying value of the liability.

The following is a description of the policies for subsequent measurement of financial assets and financial liabilities.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets at amortized cost

These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

Financial assets at FVOCI

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. Unlike IAS 39, the accumulated fair value reserve related to these investments will never be reclassified to profit and loss.

Financial liabilities at amortized cost

These liabilities are subsequently measured at amortized cost using the effective interest method. Interest expenses, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

¹ The Corporation has irrevocably elected to present subsequent changes in the fair value of investments in entities other than subsidiaries and associates in Other Comprehensive Income.

DIAGNOS Inc.

Impairment of financial assets

The Corporation uses the expected credit losses impairment model with respect to its financial assets carried at amortized cost. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since the initial recognition of the respective financial instrument. The Corporation accounts for expected credit losses over the life of financial assets measured at amortized cost. Expected credit losses over the life of the asset are expected credit losses for all of the default events that a financial instrument may experience over its expected life. The assessment of expected credit losses reflects reasonable and justifiable information about past events, current circumstances and forecasts of events and economic conditions and takes into account the factors specific to the accounts receivable, the general condition of the economy and a current as well as expected appreciation of the conditions prevailing at the balance sheet date, including the time value of the money, if any.

4. Critical accounting judgments and key sources of estimation uncertainty

In preparing these interim condensed consolidated financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. IAS 34.15, 16A(d), 28 The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements, except for new significant judgments and key sources of estimation uncertainty related to the application of IFRS 15 and IFRS 9, which are described above.

5. Short-term investments

As at

December 31, 2018	March 31, 2018
-------------------	----------------

\$

Guaranteed investment certificates, bearing interest between 0.85% and 2.20% (March 31, 2018 - 0.85% and 1.75%) and maturing between January 22, 2019 and January 13, 2020 (March 31, 2018 - June 13, 2018 and January 22, 2019)

800,622	85,984
---------	--------

Guaranteed investment certificates other than guaranteed investment certifications pledged as security are cashable without any penalties and therefore are presented as "current" in the statement of financial position.

Guaranteed investment certificates in the amount of \$50,000 (March 31, 2018 - \$80,000) are pledged as security for an account payable of \$33,309 (March 31, 2018 - \$35,921).

6. Accounts receivable

As at

December 31, 2018	March 31, 2018	
\$		
Customers	115,126	357,334
Tax credits on research and development expenses	164,541	99,541
Demand loan bearing annual interest rate of 4% (note 19)	45,294	46,749
Sales commissions advance, no interest bearing (note 19)	20,841	21,558
Sales taxes	20,590	1,146
Deposits	1,350	3,089
Others	70,723	1,715
438,465	531,132	

All amounts are due in the short term. The net carrying amounts are a reasonable approximation of their fair value.

DIAGNOS Inc.

7. Investments

	Number of companies	As at	
		December 31, 2018	March 31, 2018
		\$	
Shares of publicly traded companies	2 (March 31, 2018 - 2)	6,000	55,719
Shares of private companies	3 (March 31, 2018 - 3)	-	-
Shares of associates	0 (March 31, 2018 - 2)	-	421,084
		<u>6,000</u>	<u>476,803</u>

Investments in publicly traded companies and private companies over which the Corporation does not exercise significant influence are classified as financial assets at fair value through other comprehensive income.

As at December 31, 2018, Shares of associates include 48 common shares, or 48% (March 31, 2018 – same), of SARL Diagnos Medical, an Algerian corporation. Investments in associates are initially recorded at cost and are subsequently adjusted to reflect the Corporation's share in the net profit or loss of the associate and impairment loss. During the period, SARL Diagnos Medical was inactive.

The following table discloses changes in investments:

	Nine-month period ended	
	December 31,	
	2018	2017
	\$	
Balance, beginning of period	476,803	-
Addition in shares	-	914,292
Share of loss from associate including an impairment loss	-	(142,564)
Proceeds from disposal of shares of an associate	(436,369)	-
Management fees	2,500	-
Loss on disposal of investments	(25,507)	-
Realized loss on disposal of available-for-sale financial assets	25,507	-
Net change in value	(36,934)	25,182
Balance, end of period	6,000	796,910

8. Accounts payable and accrued liabilities

	As at	
	December 31, 2018	March 31, 2018
	\$	
Accounts payable and accrued liabilities	213,220	281,609
Interests payable and accrued	314,338	190,755
Salaries and benefits	83,987	110,791
Sales and withholding taxes	39,244	31,817
	<u>650,789</u>	<u>614,972</u>

DIAGNOS Inc.

9. Convertible notes

	Number	As at	
		December 31, 2018	March 31, 2018
		\$	
Unsecured convertible promissory notes	20 (March 31, 2018 - 20)	1,000,000	1,000,000
Fair value discount		(129,914)	(165,895)
Issue expenses		(4,195)	(4,195)
		<u>865,891</u>	<u>829,910</u>

During the quarter ended December 31, 2018, the Corporation issued 900,000 common shares at a deemed price of \$0.05 in payment for a debt of \$45,000 related to interests payable on unsecured convertible notes amounting to \$900,000 (see note 12). As at December 31, 2018, interests amounting to \$5,000 were in default of payment.

During the quarter ended December 31, 2017, as part of a private placement, the Corporation issued \$1,000,000 worth of unsecured convertible and redeemable notes (each a "Q3-2018 Note"). The Q3-2018 Notes bear interest at an annual rate of 10%, and will mature on October 13 and 23, 2020 (the "Maturity Date"). At the sole option of the Q3-2018 Note holders, the principal amount of the Q3-2018 Notes may be converted at any time, in whole or in part, into common shares of the Corporation (each a "Share") at a price of \$0.16 per Share. Any accrued interest on the principal, at the time of conversion, will be immediately payable in cash. If, at any time after the first anniversary of the Q3-2018 Note and until maturity, the volume weighted average price of the Shares on the TSX Venture Exchange is equal to or higher than \$0.28 for 20 consecutive trading days, the Q3-2018 Notes shall be redeemable, in whole or in part, at the sole option of the Corporation, into Shares of the Corporation at a price of \$0.16 per Share. Any accrued interest on the principal, at time of redemption, will be immediately payable in cash. As part of the private placement, 1,000,000 stock warrants (each a "Warrant") were issued to the Q3-2018 Note holders entitling the holder to purchase one Share of the Corporation per Warrant at a price of \$0.22 per Share for a period of 18 months from the date of issuance.

The fair value of the Q3-2018 Notes has been established at \$799,100 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	10%
Interest payment frequency:	2 per year	Effective interest rate:	20%

Of the difference of \$200,900 between the nominal value of the Notes, \$1,000,000, and its fair value of \$799,100, an amount of \$136,130 (net of deferred tax liability of \$49,081) has been allocated to the conversion options and an amount of \$11,531 (net of deferred tax liability of \$4,158) has been allocated to the stock warrants prorated based on their respective fair values using the Black-Scholes option pricing model with the following weighted average assumptions:

Stock warrants:

Expected life:	18 months	Risk-free interest rate:	1.67%
Liquidity discount:	25%	Volatility:	96.48%

Conversion options:

Expected life:	3 years	Risk-free interest rate:	1.67%
Liquidity discount:	25%	Volatility:	96.48%

DIAGNOS Inc.

10. Convertible debentures

	As at	
	December 31, 2018	March 31, 2018
	\$	
Secured convertible debentures	4,940,000	4,140,000
Fair value discount	(411,581)	(517,869)
Compounded interest expense	192,876	179,520
Issue expenses	(182,086)	(166,321)
	4,539,209	3,635,330
Secured convertible debentures - short term	1,636,258	-
Secured convertible debentures - long term	2,902,951	3,635,330

As at December 31, 2018, interests on secured convertible debentures amounting to \$168,750 were in default of payment.

During the quarter ended September 30, 2018, as part of a private placement, the Corporation issued for \$800,000 worth of senior secured convertible debentures (each a "Q2-2019 Debenture"). The Q2-2019 Debentures bear interest at an annual rate of 10%, and will mature on July 4, 2021 (the "Maturity Date"). At the sole option of the Q2-2019 Debenture holders, the principal amount of the Q2-2019 Debentures may be converted at any time, in whole or in part, into common shares of the Corporation (each a "Share") at a price of \$0.10 per Share. Any accrued interest on the principal, at the time of conversion, will be immediately payable in cash. If, at any time after the first anniversary of the Q2-2019 Debenture and until maturity, the volume weighted average price of the Shares on the TSX Venture Exchange is equal to or higher than \$0.18 for 20 consecutive trading days, the Q2-2019 Debentures shall be redeemable, in whole or in part, at the sole option of the Corporation, into Shares of the Corporation at a price of \$0.10 per Share. Any accrued interest on the principal, at time of redemption, will be immediately payable in cash. As part of the private placement, 200,000 stock warrants (each a "Warrant") were issued to the Q2-2019 debenture holders entitling the holder to purchase one Share of the Corporation per Warrant at a price of \$0.15 per Share for a period of 18 months from the date of issuance.

The fair value of the Q2-2019 Debentures has been established at \$639,280 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	10%
Interest payment frequency:	2 per year	Effective interest rate:	21.17%

Of the difference of \$160,720 between the nominal value of the Debentures, \$800,000, and its fair value of \$639,280, an amount of \$134,013 has been allocated to the conversion options and an amount of \$26,707 has been allocated to the stock warrants prorated based on their respective fair values using the Black-Scholes option pricing model with the following weighted average assumptions:

Stock warrants:

Expected life:	18 months	Risk-free interest rate:	2.35%
Liquidity discount:	25%	Volatility:	65.73%

Conversion options:

Expected life:	3 years	Risk-free interest rate:	2.35%
Liquidity discount:	25%	Volatility:	65.73%

DIAGNOS Inc.

During the quarter ended June 30, 2017, as part of a private placement, the Corporation issued for \$2.61 million worth of senior secured convertible debentures (each a "Q1-2018 Debenture"). The Q1-2018 Debentures bear interest at an annual rate of 10%, and will mature on April 13, 2020 (the "Maturity Date"). At the sole option of the Q1-2018 Debenture holders, the principal amount of the Q1-2018 Debentures may be converted at any time, in whole or in part, into common shares of the Corporation (each a "Share") at a price of \$0.15 per Share. Any accrued interest on the principal, at the time of conversion, will be immediately payable in cash. If, at any time after the first anniversary of the Q1-2018 Debenture and until maturity, the volume weighted average price of the Shares on the TSX Venture Exchange is equal to or higher than \$0.27 for 20 consecutive trading days, the Q1-2018 Debentures shall be redeemable, in whole or in part, at the sole option of the Corporation, into Shares of the Corporation at a price of \$0.15 per Share. Any accrued interest on the principal, at time of redemption, will be immediately payable in cash. At the sole option of the Corporation, at any time after the first anniversary of the Q1-2018 Debenture and until maturity, it may repay all or part of the outstanding Q1-2018 Debentures by making a cash payment equal to the principal amount of the Q1-2018 Debentures plus a premium of 25% of the principal amount owing. Any accrued interest on the principal, at time of early repayment, will be immediately payable in cash. As part of the private placement, 5,220,000 stock warrants (each a "Warrant") were issued to the Q1-2018 debenture holders entitling the holder to purchase one Share of the Corporation per Warrant at a price of \$0.22 per Share for a period of 18 months from the date of issuance.

The fair value of the Q1-2018 Debentures has been established at \$2,085,650 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	10%
Interest payment frequency:	2 per year	Effective interest rate:	20%

Of the difference of \$524,350 between the nominal value of the Debentures, \$2,610,000, and its fair value of \$2,085,650, an amount of \$332,232 (net of deferred tax liability of \$119,785) has been allocated to the conversion options and an amount of \$53,165 (net of deferred tax liability of \$19,168) has been allocated to the stock warrants prorated based on their respective fair values using the Black-Scholes option pricing model with the following weighted average assumptions:

Stock warrants:

Expected life:	18 months	Risk-free interest rate:	0.86%
Liquidity discount:	25%	Volatility:	101.19%

Conversion options:

Expected life:	3 years	Risk-free interest rate:	0.86%
Liquidity discount:	25%	Volatility:	101.19%

On July 29 and August 7, 2015, as part of a private placement, the Corporation issued \$2.29 million of senior secured convertible debentures (each a "Debenture"). The Debentures bear interest at an annual rate of 10%, and will mature on July 29, 2019 (the "Maturity Date"). Interest on the Debentures is calculated from their date of issue and will be paid quarterly in arrears beginning October 29, 2016. Interest for the first year will be paid at the Maturity Date and will be compounded annually. At the sole option of the Debenture holders, the principal amount of the Debentures may be converted at any time, in whole or in part, into common shares of the Corporation ("Common Shares") at a price of \$0.10 per Common Share. Any accrued interest on the principal, at the time of conversion, will be immediately payable in cash.

The fair value of the Debentures has been established at \$1,743,550 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	4 years	Nominal interest rate:	10%
Interest payment frequency:	4 per year	Effective interest rate:	20.03%

The fair value of the conversion options has been established at \$546,450 resulting from the difference between the nominal value of the Debentures, \$2,290,000 and its fair value of \$1,743,550.

During the year ended March 31, 2018, Debentures in the amount of \$90,000 were converted to common shares at a conversion price of \$0.06 (March 31, 2017 - \$670,000 at a conversion price of \$0.10) and, as a result, Debentures in the amount of \$1,530,000 remain outstanding as at period end.

DIAGNOS Inc.

11. Leases

	As at	
	December 31, 2018	March 31, 2018
	\$	
Finance leases	82,507	55,307
Lease fair value discount	(2,919)	(6,480)
	<u>79,588</u>	<u>48,827</u>
Finance leases - short term	<u>38,918</u>	<u>16,238</u>
Finance leases - long term	<u>40,670</u>	<u>32,589</u>

During the quarter ended December 31, 2018, the Corporation entered into one finance lease agreement for the purchase of computer equipment. The minimum monthly payment amount to \$1,410 for a term of 36 months ending in December 2021. The fair value of the lease has been established at \$47,063 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	4.99%
Payment frequency:	12 per year	Effective interest rate:	4.99%

During the quarter ended December 31, 2017, the Corporation entered into one finance lease agreement for the purchase of computer equipment. The minimum monthly payment amount to \$732 for a term of 36 months ending in December 2020. The fair value of the lease has been established at \$22,247 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	0%
Payment frequency:	12 per year	Effective interest rate:	12%

During the year ended March 31, 2017, the Corporation entered into two finance lease agreements for the purchase of computer equipment. The minimum monthly payments amount to \$1,475 for a term of 36 months ending in November and December 2019. The fair value of the leases has been established at \$44,792 using the discounted cash flows valuation method with the following weighted average assumptions:

Maturity:	3 years	Nominal interest rate:	0%
Payment frequency:	12 per year	Effective interest rate:	12%

DIAGNOS Inc.

12. Share capital

Share capital is composed of common shares without par value of which 212,931,265 are issued and outstanding as at December 31, 2018 (March 31, 2018 – 172,421,265). All the shares have identical rights with respect to the distribution of dividends and the repayment of capital. Each share confers the right to one vote at the annual general meeting of shareholders. The Corporation is authorized to issue an unlimited number of common shares.

The following table presents the changes to share capital which have occurred during the nine-month period ended December 31, 2018:

	Number of common shares	\$
Balance, beginning of period	172,421,265	21,881,166
Private placement, net of issue expenses	39,610,000	1,357,837
Interests paid in common shares (note 9)	900,000	45,000
Balance, end of period	212,931,265	23,284,003

The following table presents the changes to share capital which have occurred during the nine-month period ended December 31, 2017:

	Number of common shares	\$
Balance, beginning of period	149,277,729	20,368,019
Exercise of stock warrants	3,642,539	235,881
Conversion of debentures	18,066,664	1,140,000
Exercise of stock options	1,434,333	137,266
Balance, end of period	172,421,265	21,881,166

DIAGNOS Inc.

Stock option plan

The Corporation maintains a stock option plan for its directors, key employees and consultants for which vested options over three years can be exercised in order to acquire common shares. Effective July 21, 2017, stock option grants vest at 50% per year, commencing with the first anniversary of the grant and can be exercised over five years. Stock options granted before July 21, 2017 vest at 33.33% per year, commencing with the first anniversary of the grant. The conditions of exercise are determined by the Board of Directors in accordance with the rules of the TSX Venture Exchange. The stock options are usually granted at the share price at the close of market on the day preceding the date of grant.

The stock option plan provides that the maximum number of common shares, which may be reserved for issuance to any one participant pursuant to share options, may not exceed 5% of the common shares outstanding. The maximum number of common shares that may be reserved for issuance to insiders of the Corporation may not exceed 10% of the common shares issued and outstanding on the grant date. The maximum number of stock options which the Corporation is authorized to issue is 20,000,000. As at December 31, 2018, the outstanding number of stock options available for issuance was 3,006,406 (March 31, 2018 – 4,452,406).

During the three-month period ended June 30, 2018, the Corporation granted 4,070,000 stock options. The weighted-average fair value of each stock option grant is estimated at \$0.04 for the three-month period ended June 30, 2018 (year ended March 31, 2018 - \$0.03) and is calculated using the Black - Scholes option pricing model with the following weighted average assumptions:

Expected life:	5 years (year ended March 31, 2018 – 5 years)	Risk-free interest rate:	1.60% (year ended March 31, 2018 – 1.60%)
Dividend yield:	0% (year ended March 31, 2018 – 0%)	Expected Volatility:	96.54% (year ended March 31, 2018 - 95.77% to 99.41%)
Average exercise price at date of grant:	\$0.075 (year ended March 31, 2018 - \$0.13)	Average share price at date of grant:	\$0.075 (year ended March 31, 2018 - \$0.13)

The expected volatility was calculated on the Corporation's share prices over the last 5 years.

The following table presents the changes which have occurred for the comparative nine-month period ended December 31, 2018, with respect to stock options.

	Nine-month period ended December 31, 2018		Nine-month period ended December 31, 2017	
	Number of stock options	Weighted- average exercise price (\$)	Number of stock options	Weighted- average exercise price (\$)
Outstanding, beginning of year	12,426,684	0.10	10,771,349	0.09
Granted	4,070,000	0.08	4,650,000	0.12
Exercised	-	-	(1,434,332)	0.10
Forfeited	(2,100,000)	0.08	(548,333)	0.10
Expired	(524,000)	0.10	(862,000)	0.16
Outstanding, end of year	13,872,684	0.10	12,576,684	0.10

DIAGNOS Inc.

13. Reserve

Nine-month period ended December 31, 2018				
	Stock warrants	Conversion options	Stock options	Total
	\$			
Balance, beginning of year	3,951,170	1,067,893	2,513,569	7,532,632
Private placement	692,317	134,013	-	826,330
Issue expenses	(6,070)	(6,449)	-	(12,519)
Stock-based compensation	-	-	200,846	200,846
Balance, end of year	4,637,417	1,195,457	2,714,415	8,547,289

Nine-month period ended December 31, 2017				
	Stock warrants	Conversion options	Stock options	Total
	\$			
Balance, beginning of year	3,891,631	632,214	2,341,886	6,865,731
Private placement	88,022	637,228	-	725,250
Issue expenses	(5,157)	(32,684)	-	(37,841)
Stock-based compensation	-	-	124,917	124,917
Balance, end of year	3,974,496	1,236,758	2,466,803	7,678,057

Stock warrants

During the quarter ended December 31, 2018, in connection with the financings described in note 12 above for the same period, the Corporation issued 37,310,000 stock warrants entitling the holders to purchase (i) 10,000,000 common shares (each a "Share") of the Corporation at a price of \$0.07 per Share for a period of eighteen months ending May 1, 2020, (ii) 20,660,000 common shares (each a "Share") of the Corporation at a price of \$0.05 per Share for a period of twenty-four months ending November 9, 2020 and (iii) 6,650,000 common shares (each a "Share") of the Corporation at a price of \$0.06 per Share for a period of eighteen months ending June 12, 2020. The fair value of the warrants has been established at \$119,917, \$410,999 and \$96,636 respectively.

During the quarter ended September 30, 2018, in connection with the financing described in note 10 above for the same period, the Corporation issued 3,200,000 stock warrants entitling the holders to purchase 3,200,000 common shares (each a "Share") of the Corporation at a price of \$0.15 per Share for a period of eighteen months ending January 4, 2020. The fair value of the warrants has been established at \$26,707 as described in note 10.

During the quarter ended September 30, 2018, in connection with the financing described in note 12 above for the same period, the Corporation issued 2,300,000 stock warrants entitling the holders to purchase (i) 800,000 common shares (each a "Share") of the Corporation at a price of \$0.10 per Share for a period of eighteen months ending December 14, 2019 and (ii) 1,500,000 common shares (each a "Share") of the Corporation at a price of \$0.10 per Share for a period of eighteen months ending March 11, 2020. The fair value of the warrants has been established at \$38,058.

DIAGNOS Inc.

The following table presents the changes to stock warrants which have occurred for the comparative nine-month periods ended December 31, 2018:

	Nine-month period ended December 31, 2018		Nine-month period ended December 31, 2017	
	Number of stock warrants	Weighted average exercise price (\$)	Number of stock warrants	Weighted average exercise price (\$)
Balance, beginning of period	6,220,000	0.22	3,907,388	0.07
Private placement	42,810,000	0.07	6,220,000	0.22
Exercised	-	-	(3,642,539)	0.06
Expired	(5,220,000)	0.22	(264,849)	0.15
Balance, end of period	43,810,000	0.07	6,220,000	0.22

14. Commitments

The Corporation rents offices in Canada under a lease that expires in September 2019. As of April 1, 2018, the Corporation is committed to making minimum annual lease payments of \$109,944 for the duration of the lease.

DIAGNOS Inc.

15. Financial instruments and risk management

a) Presentation

As at December 31, 2018

	Amortized cost		Fair value through profit or loss		Fair value through other comprehensive income		Total	
	Fair value	Book value	Fair value	Book value	Fair value	Book value	Fair value	Book value
	\$							
Financial assets								
Cash	417,982	417,982					417,982	417,982
Short-term investments			800,622	800,622			800,622	800,622
Accounts receivable	253,335	253,335					253,335	253,335
Investments - shares					6,000	6,000	6,000	6,000
Financial liabilities								
Accounts payable and accrued liabilities	527,558	527,558					527,558	527,558
Convertible Notes	865,891	865,891					865,891	865,891
Convertible Debentures	4,539,209	4,539,209					4,539,209	4,539,209

As at March 31, 2018

	Amortized cost		Fair value through profit or loss		Fair value through other comprehensive income		Total	
	Fair value	Book value	Fair value	Book value	Fair value	Book value	Fair value	Book value
	\$							
Financial assets								
Cash	150,291	150,291					150,291	150,291
Short-term investments			85,984	85,984			85,984	85,984
Accounts receivable	430,445	430,445					430,445	430,445
Investments - shares					55,719	55,719	55,719	55,719
Financial liabilities								
Accounts payable and accrued liabilities	472,364	472,364					472,364	472,364
Convertible Notes	829,910	829,910					829,910	829,910
Convertible Debentures	3,635,330	3,635,330					3,635,330	3,635,330

X

b) Fair value hierarchy

Financial instruments

Financial instruments recorded at fair value in the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices);
- Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified at the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

The following tables present the financial instruments recorded at fair value in the consolidated statements of financial position classified using the fair value hierarchy described above:

As at December 31, 2018				
	Level 1	Level 2	Level 3	Total financial assets at fair value
	\$			
Financial assets				
Short-term investments	800,622	-	-	800,622
Investments – shares	6,000	-	-	6,000
Total financial assets	806,622	-	-	806,622
	Level 1	Level 2	Level 3	Total financial liabilities at fair value
	\$			
Financial liabilities				
Convertible notes	-	865,891	-	865,891
Convertible debentures	-	4,539,209	-	4,539,209
Total financial liabilities	-	5,405,100	-	5,405,100

During the period, there has been no transfer of amounts between Level 1 and Level 2.

As at March 31, 2018				
	Level 1	Level 2	Level 3	Total financial assets at fair value
	\$			
Financial assets				
Short-term investments	85,984	-	-	85,984
Investments – shares	55,719	-	-	55,719
Total financial assets	141,703	-	-	141,703
	Level 1	Level 2	Level 3	Total financial liabilities at fair value
	\$			
Financial liabilities				
Convertible notes	-	829,910	-	829,910
Convertible debentures	-	3,635,330	-	3,635,330
Total financial liabilities	-	4,465,240	-	4,465,240

The Corporation has determined that the fair value of its current financial assets and liabilities measured at amortized cost approximate their carrying amounts as at the balance sheet dates because of their short-term maturity.

The fair value of short-term investments was based on quoted prices in active markets.

The fair value of loans, convertible notes and convertible debentures was estimated by discounting expected cash flows at rates offered to the Corporation for debts of the same remaining maturities and conditions.

Non-financial instruments

The fair value of leases was \$79,588 as at December 31, 2018 (\$48,827 as at March 31, 2018) and estimated by discounting expected cash flows at rates currently offered to the Corporation for debts of the same remaining maturities and conditions.

c) Risks

The Corporation is exposed to certain risks which could have a material impact on its ability to achieve its strategic growth objectives. The Corporation strives to control and mitigate its business and financial risks through management practices that require the ongoing evaluation, identification and implementation of risk mitigating measures that help reduce or eliminate risks related to its business operations.

The following describes the Corporation's main financial risks:

i. Credit Risks

In the normal course of business, the Corporation's exposure to credit risk results from the possibility that a customer or financial institution may default, in part or in whole, on their financial obligations, as they come due.

Cash and short-term investments

Cash as well as short-term investments are mainly risk-free or low-risk investments, such as cash and guaranteed term deposits held by recognized financial institutions. None of these short-term investments consist of asset-backed commercial paper. Consequently, management considers the credit risk related to cash and short-term investments to be low as at December 31, 2018 and March 31, 2018.

Customers and demand loans

In the normal course of business, the Corporation grants credit terms to its customers. The Corporation reviews and, if required, establishes allowances for doubtful accounts on a regular basis. For other accounts receivable including demand loan, the Corporation determines, on a continuing basis, the probable losses and establishes a provision to account for such losses based on the estimated realizable value.

As at December 31, 2018, 40% of accounts receivable from customers was attributable to seven customers active in the healthcare industry (82% as at March 31, 2018, from one customer). It should be noted that given the specialization of the Corporation's market niche, it is most likely that such concentration risk is expected to continue. However, from one year to the next, it is rare that the same customers make up this concentration. Despite the concentration of its customers, the credit risk is mitigated through monitoring of its customers and the additional measures available to the Corporation, as previously described.

Additionally, as at December 31, 2018:

- 19% of the net accounts receivable are over 90 days old (1% as at March 31, 2018);
- accounts receivable from customers exceeding the normal payment terms of 30 days for which no allowance was applied represented 39% of the net accounts receivable from customers (92% as at March 31, 2018).

Management is reasonably assured that its receivables will be collected, and therefore considers the credit risk related to accounts receivable to be low as at December 31, 2018 and March 31, 2018.

ii. Liquidity Risks

Liquidity risk is the risk that the Corporation cannot meet its obligations as they come due. On an ongoing basis, the Corporation monitors and manages its actual and projected cash flows, with the primary objectives of maintaining liquidity and financial flexibility. In addition, the Corporation's policy is to target contracts that will generate positive cash flows throughout their execution.

As at December 31, 2018, accounts payable, convertible notes, convertible debentures and leases that were due in the next 12 months totalled \$2,860,155 including non-financial instruments (March 31, 2018 - \$1,012,848). Considering the available liquidities to meet its obligations, the Corporation's exposure to liquidity risk as at December 31, 2018 and March 31, 2018 is high and is dependent on the Corporation's ability in securing additional financing and achieving and maintaining profitable operations. Refer to going concern assumptions in note 1.

iii. Interest Rate Risk

Interest rate risk refers to the adverse consequences of interest rate changes on the Corporation's cash flows, financial position and income. Interest rate changes directly impact the fair value of the fixed interest rate accounts of the financial statements.

The Corporation is not exposed to interest risk since its financial instruments bear interest at fixed rate and are presented at amortized cost.

iv. Market Risk

Market risk refers to the adverse consequences of stock price changes on the Corporation's investments in shares. Investments in shares are currently mainly composed of shares of corporations traded on the TSX Venture Exchange. As at December 31, 2018, considering the value of investments in shares of \$6,000 (March 31, 2018 – \$55,719), a change of 50% in the market value of these shares would not have a significant impact on the Corporation's expenses.

v. Exchange Rate Fluctuations Risk

Exchange rate fluctuations risk refers to the adverse consequences of exchange rate changes on the Corporation's cash flows, financial position and income. During the period, revenues and expenses arose from transactions occurring in Canadian dollars and other currencies.

The Corporation is exposed to fluctuations in the currency rates of six currencies (USD, MXN, INR, PLN, AED, Euro). Movements in foreign currencies against the Canadian dollar may impact revenues, the nominal amount of certain financial assets and financial liabilities, and negatively affect the Corporation's profit or loss.

Assuming that all other variables remain constant, a 10% increase or decrease in the exchange rate of the Canadian dollar, against other currencies, would not have a significant impact on the Corporation's net loss for the nine-month periods ended December 31, 2018 and December 31, 2017.

16. Expenses by nature

	Three-month period ended		Nine-month period ended	
	December 31,		December 31,	
	2018	2017	2018	2017
	\$		\$	
Depreciation and amortization	40,943	60,788	158,279	169,106
Audit	-	2,773	53,849	64,724
Bad debt	-	-	-	6,191
Communications	12,975	18,094	37,027	43,153
Consulting fees	146,688	40,473	501,045	323,992
Equipment	2,173	3,658	12,855	14,623
Foreign exchange	797	82,026	14,985	111,278
Leasing	28,605	35,744	92,592	112,121
Legal fees	15,550	1,611	22,701	41,112
Gain on disposal of investments	17,145	-	25,507	-
Loss from associates	-	68,487	-	142,564
Marketing	13,785	30,570	41,553	78,477
Overhead	32,562	99,953	99,386	196,671
Remuneration	528,105	752,412	1,453,708	1,876,369
Tax credits	(20,000)	(20,000)	(65,000)	(60,000)
Travel and living	31,101	116,644	132,160	233,345
	<u>850,429</u>	<u>1,293,233</u>	<u>2,580,647</u>	<u>3,353,726</u>
	Three-month period ended		Nine-month period ended	
	December 31,		December 31,	
	2018	2017	2018	2017
	\$		\$	
Interest on debentures	237,580	167,445	648,016	644,898
Interest on notes	42,391	20,890	110,775	20,890
Interest on short term loans	-	-	-	4,504
Other interest expense	669	218	2,730	1,501
	<u>280,640</u>	<u>188,553</u>	<u>761,521</u>	<u>671,793</u>

17. Income taxes

As at December 31, 2018 and December 31, 2017, income taxes recoverable are composed essentially of non-capital losses. Based on available information, it is not probable that income taxes recoverable on these amounts will be realized in the near future, therefore, no deferred tax asset was recorded in these interim condensed consolidated financial statements.

Operating losses carried forward

As at March 31, 2018, the Corporation had operating tax losses available in Canada and Mexico for which no deferred assets were accounted for. The following table summarizes the expiry of the losses per fiscal jurisdiction:

	Canada	Mexico	Total
	\$		
2026	-	42,317	42,317
2027	-	263,406	263,406
2028	-	628,966	628,966
2029	1,195,772	-	1,195,772
2030	1,557,531	-	1,557,531
2031	854,384	-	854,384
2032	1,491,339	-	1,491,339
2033	1,314,805	-	1,314,805
2034	850,751	-	850,751
2035	1,958,526	-	1,958,526
2036	1,972,657	-	1,972,657
2037	1,496,272	-	1,496,272
2038	1,799,391	-	1,799,391
	<u>14,491,428</u>	<u>934,689</u>	<u>15,426,117</u>

As at March 31, 2018, the Corporation also has investment tax credits totalling \$1,760,351 (March 31, 2017 - \$1,683,281) available to offset future Canadian federal income taxes payable. The potential benefit of the investment tax credits has not been recognized in the accounts.

18. Segment information

The Corporation is active in one reportable segment, healthcare services. It provides image analysis services through CARA (Computer Assisted Retinal Analysis), a software tool which assists health specialists in the detection of diabetic retinopathy. Up to May 25, 2017, the Corporation was also active in the mining sector.

Revenue by country:

	Three-month period ended December 31,				Nine-month period ended December 31,			
	2018	2017			2018	2017		
	Healthcare	Healthcare	Mining	Total	Healthcare	Healthcare	Mining	Total
	\$				\$			
Canada	68,917	8,385	-	8,385	157,615	8,735	320,000	328,735
United States of America	18,501	7,647	-	7,647	53,407	9,618	-	9,618
Mexico	-	920,942	-	920,942	-	1,171,037	-	1,171,037
United Arab Emirates	6,338	-	-	-	18,638	18,420	-	18,420
Saudi Arabia	523	-	-	-	3,776	5,082	-	5,082
Slovakia	232	452	-	452	1,936	4,972	-	4,972
Bangladesh	-	-	-	-	-	5,754	-	5,754
Poland	-	-	-	-	-	1,985	-	1,985
Nigeria	-	-	-	-	(50)	625	-	625
	94,511	937,426	-	937,426	235,322	1,226,228	320,000	1,546,228

65% of revenues from Canada, for the nine-month period ended December 31, 2018, were attributable to data interpretation consulting services rendered to one company active in the mining sector (nine-month period ended December 31, 2017 - 3%). As this line of business is not strategic to the development of the Corporation, revenue amounts from consulting services are not presented separately from healthcare services.

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers:

	As at	
	December 31, 2018	March 31, 2018
	\$	
Receivables	115,126	357,334
Contract liabilities	66,617	31,893

The following table discloses changes in contract liabilities:

	Nine-month period ended	
	December 31,	
	2018	2017
	\$	
Balance, beginning of period	31,893	78,200
Invoiced before recognition as revenue	63,275	18,999
Recognized as revenue	(28,551)	(78,200)
Balance, end of period	66,617	18,999

Unchanged from the last reporting period, tangible assets are mainly located in Canada and Mexico.

19. Related party transactions

The Corporation's related parties include its subsidiaries and associate entity as well as the Corporation's key management personnel. Key management personnel includes directors and officers.

The following table presents the transactions with key management personnel during the three-month and nine-month periods ended December 31, 2018 and December 31, 2017:

	Three-month period ended		Nine-month period ended	
	December 31		December 31,	
	2018	2017	2018	2017
	\$		\$	
Base salary	130,000	130,000	390,000	382,500
Stock-based compensation	35,017	63,826	105,049	127,652
Incentives	45,000	-	70,000	150,000
Sales commissions	-	65,181	1,380	110,971
Interest on demand loan	485	606	1,455	1,819
Payment of interest on demand loan	(485)	(606)	(1,455)	(1,819)
	<u>210,017</u>	<u>259,007</u>	<u>566,429</u>	<u>771,123</u>

The following table present the outstanding balances with key management personnel:

	As at	
	December 31, 2018	March 31, 2018
	\$	
Demand loan receivable, annual interest rate of 4%	45,294	46,749
Cash advance, no interest	20,841	21,558
Convertible debentures, annual nominal interest rate of 10%	(30,000)	(30,000)
Convertible notes, annual nominal interest rate of 10%	(500,000)	(500,000)

20. Discontinued operations

As part of the May 25, 2017 sale of the assets of the mining division to Majescor Resources Inc. (now Albert Mining Inc. or "Albert"), the Corporation's operations related to the mining division were identified as discontinued operations.

The impact on the statements of cash flows is as follows:

	Nine-month period ended December 31,	
	2018	2017
	\$	
Net cash flows from operating activities	-	247,829

The Corporation received 8,000,000 common shares of Majescor Resources Inc. valued at \$0.08 per share for an aggregate purchase price of \$640,000 in payment for all of the assets of the mining division. The carrying amount of these assets was \$16,081.

During the quarter ended June 30, 2018, the Corporation proceeded with the disposal of all of the Albert's shares it held as at March 31, 2018 at an average selling price of \$0.04 (see note 7).

21. Other income

Government grants

The Corporation received the support of the Quebec government through the Créativité Québec program, administered by Investissement Québec (IQ), to presents a technological showcase at the Centre Hospitalier de l'Université de Montréal (CHUM). The government grant could reach \$159,335 depending on the expenses incurred until the end of the project scheduled through May 31, 2019.

During the nine-month period ended December 31, 2018, when the terms attached to the grant were complied with, the grant in the amount of \$15,857 was recognized in "Other income" in these interim condensed consolidated financial statements.

Head Office

DIAGNOS Inc.
7005 Taschereau Blvd.
Suite 340
Brossard, Quebec J4Z 1A7
450 678-8882 or 877 678-8882

Stock Exchange Listing

DIAGNOS Inc. shares are listed on the TSX Venture Exchange under the symbol ADK and on the OTCQB under the symbol DGNOF.

Transfer Agents and Registrar

Computershare Trust Company of Canada

Auditor

Raymond Chabot Grant Thornton LLP